Gain Therapeutics Reports $4.7 Million Net Loss in Q2 2026, Progress on Rexaceract Development

Gain Therapeutics, Inc. has reported its financial results for the second quarter of 2026, revealing a net loss of $4.7 million, a decrease from the $5.8 million loss recorded in the same period of the previous year. For the first half of 2026, the company reported a net loss of $10.3 million, slightly down from $10.4 million in the first half of 2025. The reduction in losses is attributed to a decrease in operating expenses, which totaled $4.7 million for the quarter, down from $5.1 million a year earlier, and $10.0 million for the six months, compared to $9.5 million in the prior year. The company’s cash and cash equivalents stood at $13.1 million as of June 30, 2026, a decline from $20.8 million at the end of 2025.

The company’s research and development expenses decreased to $2.1 million for the second quarter of 2026, down from $2.8 million in the same quarter of 2025. For the first half of 2026, R&D expenses were $4.9 million, compared to $5.0 million in the prior year. This decline is primarily due to lower costs associated with the lead program compound, rexaceract, for the treatment of Parkinson’s disease, as well as optimization of the pipeline. General and administrative expenses, however, increased to $2.5 million for the second quarter, up from $2.3 million a year earlier, reflecting higher professional fees and personnel costs.

In terms of operational developments, Gain Therapeutics has made significant progress with its lead product candidate, rexaceract, which is in clinical development for Parkinson’s disease. The company has completed two clinical studies and is currently conducting a Phase 1b study, with plans to initiate a Phase 2 study in the third quarter of 2026 following FDA authorization. The company has also been active in its financing efforts, raising $1.8 million through its at-the-market (ATM) program during the first half of 2026, although this is a decrease from $4.9 million raised in the same period of 2025.

Looking ahead, Gain Therapeutics faces substantial challenges, including the need for additional capital to fund ongoing operations and development activities. The company has indicated that its current cash resources may not be sufficient to sustain operations beyond the second quarter of 2027, raising concerns about its ability to continue as a going concern. Management is exploring various strategies to enhance liquidity, including potential cost reductions and seeking additional financing through equity offerings or collaborations. The company remains focused on advancing its clinical programs while navigating the complexities of the biotechnology landscape.